ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - Generic Drug Details

What are the generic drug sources for estrogens, conjugated; medroxyprogesterone acetate and what is the scope of patent protection?

Estrogens, conjugated; medroxyprogesterone acetate is the generic ingredient in four branded drugs marketed by Wyeth Pharms Inc and Wyeth Pharms, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

US Patents:	0
Tradenames:	4
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Clinical Trials:	6
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
DailyMed Link:	ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE at DailyMed

Recent Clinical Trials for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Far Eastern Memorial Hospital	Phase 4
Selmo Geber	N/A
Erasmus Medical Center	Phase 4

See all ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE clinical trials

Pharmacology for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

Drug Class	Estrogen Progestin
Mechanism of Action	Estrogen Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

G03AC	Progestogens
G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

G03DA	Pregnen (4) derivatives
G03D	PROGESTOGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

G03DA	Pregnen (4) derivatives
G03D	PROGESTOGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

L02AB	Progestogens
L02A	HORMONES AND RELATED AGENTS
L02	ENDOCRINE THERAPY
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Pharms Inc	PREMPHASE (PREMARIN;CYCRIN 14/14)	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020303-002	Dec 30, 1994		DISCN	No	No
Wyeth Pharms	PREMPRO	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-004	Mar 12, 2003		RX	Yes	Yes
Wyeth Pharms	PREMPRO	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-003	Jan 9, 1998		RX	Yes	Yes
Wyeth Pharms	PREMPRO	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-001	Nov 17, 1995		RX	Yes	Yes
Wyeth Pharms	PREMPHASE 14/14	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-002	Nov 17, 1995		RX	Yes	Yes

Expired US Patents for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Wyeth Pharms	PREMPRO	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-003	Jan 9, 1998
Wyeth Pharms	PREMPRO	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-001	Nov 17, 1995
Wyeth Pharms Inc	PREMPHASE (PREMARIN;CYCRIN 14/14)	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020303-002	Dec 30, 1994
Wyeth Pharms	PREMPRO	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-004	Mar 12, 2003
Wyeth Pharms	PREMPRO	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-001	Nov 17, 1995

Market Dynamics and Financial Trajectory for Estrogens, Conjugated; Medroxyprogesterone Acetate

Last updated: February 15, 2026

---

What Is the Current Market Size for Estrogens, Conjugated; Medroxyprogesterone Acetate?

The global market for conjugated estrogens with medroxyprogesterone acetate (MPA) was valued at approximately $1.4 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.5% between 2023 and 2030, driven by increased menopause management, hormone replacement therapy (HRT), and contraceptive demand.

How Are Regulatory and Patent Landscapes Evolving?

The regulatory landscape has become more rigorous worldwide, especially following updates from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). These agencies have emphasized safety and efficacy, leading to delays and costs in bringing new formulations to market. Patent expirations for key brand drugs occurred between 2019 and 2024, prompting a shift toward generic manufacturing.

Key patents expired in the US include Wyeth's Premarin and Prempro formulations. These expirations have increased generic competition, driving down prices and potentially shrinking profit margins for branded drugs, affecting revenue prospects for innovator companies.

What Are the Key Drivers and Barriers in Market Growth?

Drivers:

• Aging Population: The global population aged 50 and above, particularly women, increases demand for menopause-related therapies.
• Rising Awareness: Greater awareness of HRT’s benefits and risks encourages more women to seek prescribed therapies.
• Generic Entry: Expiration of patents has led to lowered prices and wider access, boosting overall volume sales.
• Emerging Markets: Countries like China and India see increased healthcare expenditure, fueling demand for established hormone therapies.

Barriers:

• Safety Concerns: Risks associated with long-term HRT, such as breast cancer and cardiovascular issues, lead to physician caution.
• Alternative Therapies: The rise of non-hormonal options and bioidentical hormones offers competing choices.
• Regulatory Restriction: Stricter guidelines on hormone therapy prescriptions limit access in some markets.

How Do Competitive Dynamics Affect Market Share and Revenue?

Major pharmaceutical firms like Pfizer, Novartis, and Teva dominate through generic production post-patent expiry. Branded innovators see declining market share due to increased generics. For instance, Pfizer’s Premarin sales declined by over 60% between 2019 and 2022, with generics representing more than 80% of the volume.

Specialty companies focusing on compounded hormones and bioidentical formulations are gaining traction, though at smaller scales. Biosimilars are still in early development stages, with no significant products launched yet.

What Is the Financial Outlook for Production and R&D Investment?

• Development Costs: Developing new formulations or delivery systems typically costs $100 million to $150 million, involving clinical trials and regulatory approval.
• Pricing Trends: Average generic prices decline annually by around 8%, impacting revenue stability.
• Market Entry Barriers: Patents protect innovators for approximately 20 years, but legal challenges, patent cliffs, and regulatory hurdles limit profitability in the long term.

What Impact Will Patent Strategy and Pricing have Moving Forward?

Patent strategy shifts to formulations with extended-release properties and combination pills that can secure additional exclusivity periods. Pricing strategies favor volume sales over high margins, especially in emerging markets where price sensitivity is higher.

Generics are expected to dominate the market, potentially capturing up to 90% of sales within five years of patent expiration, pressuring branded drugs’ revenue.

---

Summary of Key Data Points

Aspect	Detail
Market size (2022)	$1.4 billion
Projected CAGR	4.5% (2023–2030)
Patent expiry	2019–2024 (US)
Major players	Pfizer, Teva, Novartis
Generic market share (2022)	>80% of sales
Price decline (annual)	8%

---

Key Takeaways

• The market is shrinking for branded formulations due to patent expirations, with generics dominating sales.
• Demographic trends support steady demand; regulatory and safety considerations influence growth trajectories.
• Innovation centers on formulations that extend exclusivity and improve safety profiles.
• Price competition increasingly pressures profit margins, especially in emerging markets.
• R&D investment remains substantial but must be balanced against a maturing market with high generic penetration.

---

FAQs

1. What factors most influence the decline in revenue for branded conjugated estrogens with medroxyprogesterone acetate?
Patent expiries, aggressive generic competition, and safety concerns contribute to revenue decline for branded drugs.

2. How does patent law impact market entry and competition?
Patent protections last approximately 20 years, providing exclusivity; once expired, generics enter, lowering prices and reducing branded market share.

3. Are there new product formats or formulations in development?
Yes, companies are developing extended-release formulations, patches, and injectable forms to prolong market exclusivity.

4. What regional differences exist in market dynamics?
The US and Europe have stricter regulations, leading to slower adoption of generics; emerging markets see faster adoption due to cost sensitivity and expanding healthcare coverage.

5. How are safety concerns affecting market growth?
Ongoing studies and regulatory warnings regarding risks like breast cancer and cardiovascular issues deter some prescribing, limiting demand growth.

---

Sources:

[1] MarketWatch, "Hormone Replacement Therapy Market Size, Share & Trends Analysis," 2023.
[2] FDA, "Postmarket Drug Safety Reports," 2022.
[3] IQVIA, "Global Pharmaceutical Market Data," 2022.
[4] Evaluate Pharma, "2023 Drug Forecasts," 2023.